BiVictriX Therapeutics plc

Today is World MDS Awareness Day! 🩸 Myelodysplastic Syndromes (MDS) are a group of rare blood cancers that develop when bone marrow fails to produce enough healthy blood cells. Early detection is critical, as some forms of MDS can progress rapidly, with potentially life-threatening consequences. At BiVictriX, we are committed to advancing the fight against blood cancers, including acute myeloid leukaemia (AML) – a condition that can develop from MDS in 30% of patients. This #WorldMDSDay, we stand with the MDS Alliance to raise awareness of this condition, encourage early diagnosis through blood tests, and highlight the need for better treatment options. Our lead bispecific ADC, BVX001, is being developed specifically to target AML, the aggressive form of MDS progression. We remain dedicated to providing hope through innovative science and a commitment to improve patient outcomes. 🔍 Know the signs. Share the knowledge. Help spread the word. Learn more about MDS, its symptoms, and how you can get involved: https://lnkd.in/dpQ5g_k #MDSAwareness #AML #BloodCancerAwareness #MDS #MDSWAD2023 #bloodcount

Exciting times ahead for Bivictrix Therapeutics Ltd! 🚀 We've reached a significant milestone as we transition from our AIM listing to becoming a private company. This move allows us to accelerate the development of our cutting-edge bispecific ADCs and stay competitive in this rapidly evolving space. What’s been happening recently? 🌟 BVX002 progress: Our lead solid tumour asset has shown remarkable preclinical results in an ovarian cancer model, with data exceeding expectations. The positive results strengthen our belief in the potential of our platform for solid tumours. 🌟 More models: We're expanding our research with additional tumour models and will be sharing more efficacy and safety data soon. Stay tuned as we move closer to selecting a clinical candidate for BVX002! 🌟 Pipeline growth: We're building a proprietary library of novel antigen combinations focused on solid tumours, with more candidates on the horizon. Our lead asset, BVX001, also continues to make strong progress in terms of safety and efficacy for the treatment of acute myeloid leukaemia, AML. This transition to private status puts us in a stronger position to push forward with our groundbreaking research and bring new treatments to patients faster. Watch this space – there's more to come! 💥 #biotech #ADC #oncology #solidtumors #DrugDevelopment

Today, we join the global STEM community in celebrating #AdaLovelaceDay – a day dedicated to recognizing the achievements of women in science, technology, engineering, and maths 🔬 At Bivictrix, we believe that representation in STEM matters, and we’re proud to be a woman-led organisation at the forefront of innovation in the biotech industry. Our CEO and founder, Tiffany Thorn, has been at the helm since founding the company in 2016. Her work as a Clinical Immunologist directly inspired the development of our Bi-Cygni® technology, which leverages unique antigen "fingerprints" to directly target cancers. Ada Lovelace’s legacy is a reminder of the power of women in science, and we’re committed to empowering the next generation of female leaders in STEM. Let’s keep pushing boundaries and paving the way for more women in STEM! #ALD24 #WomenInSTEM #AdaLovelace #WomenInScience

Who’s heading to the ASH Annual Meeting in San Diego? 🇺🇸 We’re excited to share that Tiffany Thorn (CEO) and Oliver Schon (VP of R&D) will be attending the 66th American Society of Hematology (ASH) Annual Meeting & Exposition in December! This event gathers global leaders in haematology and oncology, and we look forward to connecting with fellow innovators, exchanging ideas, and sharing updates on our innovative work in antibody drug conjugates (ADCs). If you’re attending, let’s meet and explore ways we can collaborate to advance cancer therapeutics. 💡 Let us know if you’ll be in San Diego – we’d love to connect! #ASH2024 #Hematology #Oncology #CancerResearch #BiVictriX 

“We are at the forefront of bispecific ADCs, and we want to stay there” 🚀 Our CEO, Tiffany Thorn, recently spoke with Proactive's Stephen Gunnion about the major strides we’re making in oncology and the strategic decision to delist from AIM. In the video interview, Tiffany highlights: 🌟 The decision to accelerate our journey as a private company, ensuring we unlock the full potential of our pipeline. 🌟 Astonishingly positive preclinical results from our lead solid tumour program, BVX002, targeting ovarian cancer. These results have outperformed expectations and surpassed competitor benchmarks in the field of ADCs. 🌟 Plans for further tumour model studies, including breast cancer, as we continue expanding our proprietary library targeting multiple tumour types. Check out the full interview for more insights into the promising future of BiVictriX and the impact we aim to make in cancer treatment 🎥 https://lnkd.in/euni_Gjh   #BiVictriX #Oncology #CancerResearch #OvarianCancer #ADCTherapeutics #Innovation #Biotech #Healthcare

The Era of ADCs is here – but how do companies stand out in an increasingly crowded market? 🚀 A recent article from Pharmaceutical Technology highlights how ADCs (antibody-drug conjugates) have been dominating the oncology drug development market since 2023, with major pharmaceutical companies spending billions of dollars to expand their pipelines. But despite recent progress in the space, there are still a lot of concerns around the toxicities related to ADCs. One of the key challenges faced by many ADC developers? They are relying on the same limited pool of oncology targets. As David Thurston notes: “Everyone is looking for a new, novel target that can differentiate you from other companies and that will work well for a particular type of cancer." This is precisely where BiVictriX excels. Traditional antibody-based therapies often fall short because the antigens they target are found on both healthy and cancerous cells, leading to harmful on-target/off-tissue toxicities. With our groundbreaking Bi-Cygni® bispecific platform, we’ve developed an innovative approach that precisely targets twin antigen pairs exclusively present on cancer cells. This allows us to minimize toxic side effects, increase the maximum tolerated dose of our ADCs, and widen the therapeutic window. Ultimately, this means we can deliver more effective treatments for longer while significantly improving patient outcomes. Check out the link in the comment to read the full article, or get in touch with our team to learn more about our proprietary Bi-Cygni platform: info@bivictrix.com #ADCs #Oncology #CancerResearch #BiVictriX #PharmaInnovation #Antibodies

Exciting news from our BVX002 solid tumour programme! 🚀 We are delighted to share the first in vivo data from our lead solid tumour bispecific ADC programme, which marks the beginning of an exciting development journey for BVX002. In a preclinical study targeting ovarian cancer, BVX002 showed complete tumour growth inhibition and even tumour regressions for some chosen ADC doses. All tested doses were well-tolerated. Key highlights include: • Tumour growth inhibition of > 100% in the mid and high dose groups • Tumour regressions of up to 63.1% at the mid and high doses • Continued tumour shrinkage two weeks post-treatment, highlighting the durability of BVX002’s anti-cancer effects BVX002 targets a novel, cancer-specific antigen pair found in various solid tumours, including ovarian and non-small cell lung cancer, but is absent from healthy cells. Internal data suggests this antigen pair may be present in 60-70% of patients with high grade serous ovarian cancer. The next step? Filing an Investigational New Drug application with the FDA. Our CEO, Tiffany Thorn, said: "This first in vivo data marks the start of what we anticipate being an incredibly exciting preclinical data package for our lead solid tumour asset, BVX002. We are highly encouraged by the significance of the anti-tumour effect delivered by our therapeutic lead in this hard-to-treat model of ovarian cancer, which showcases the clear benefit of our proprietary bispecific ADC approach in a solid tumour setting. We look forward to providing further updates as we expedite the development of this asset." Read the full press release for more details 👉 https://lnkd.in/er24sT5v #DrugDevelopment #BVX002 #BiVictriX #Cancer #Therapeutics 

Hot off the press…our first in vivo data with our lead solid tumour asset published today in case you missed it and what fantastic data this is…

Here’s what the experts think of BVX001…    “BVX001 has a compelling preclinical profile in the AML setting and recent data further support the potential of CD7+ targeting approaches to address the poor response of this significant patient population to existing therapies."    Earlier this year, Dr Daniel Pollyea from the University of Colorado School of Medicine shared his thoughts on the potential of BVX001 alongside other leading experts in the Acute Myeloid Leukemia (AML) field.    “At this juncture, BVX001 shows promise and as a physician, I am keen to work more closely with the company as they progress towards first-in-human studies.”   Overall, the group endorsed BVX001’s first-in-class CD7+/CD33+ targeting approach, which could impact around 30% of the total AML population. Furthermore, they highlighted our emerging data showing BVX001’s potential against treatment-resistant cases and cancer recurrence. You can read more of the group’s expert thoughts in the images below, or head to the news section of our website to read about what we’ve been up to since: https://lnkd.in/eM_ggF4k #ADC #Antibody #AML #DrugDevelopment #Oncology

What’s different about our Bi-Cygni ADCs? In the rapidly evolving field of cancer treatment, the safety and efficacy of antibody-drug conjugates (ADCs) has been hampered by significant on-target and off-target toxicities. To overcome these challenges, our next-generation Bi-Cygni® ADCs are designed with a unique FLEX bispecific format. Our FLEX ADCs overcome the common pitfalls of traditional ADCs by ensuring the potent drug payload is released only within the tumor cells, minimizing harmful side effects and enabling higher, more effective dosing.  This approach is a game-changer for conditions like Acute Myeloid Leukemia (AML), where existing treatments often fail due to high toxicity and limited therapeutic windows. With BVX001, we are advancing cancer therapy by making ADCs safer, more precise, and ultimately, more effective for patients in need. #BiVictriX #CancerTherapy #ADCs #DrugDevelopment #AML